全球生物防禦市場：依疾病類型、治療方法和地區的預測（~2030年）

生物防禦市場規模預計在預測期內年複合成長率為 7.01%。

為了應對潛在的生物恐怖攻擊，各國政府正投入大量資源進行疫苗研發。政府為應對各種形式的生物恐怖主義所做的努力為生物防禦市場上的製藥公司提供了重大的擴張機會。此外，世界各國政府實施提高生物防禦能力的措施。由於研發、準備規劃、基礎設施開發以及疫苗和藥品採購資金的增加，生物防禦市場成長。

依地域的展望

2023年，北美生物防禦市場的市佔率最大。這是因為愛滋病毒、病毒性肝炎和流感等傳染病在該地區盛行。美國疾病管制與預防中心（CDC）估計，2021年美國約有 900萬人被診斷出感染流感病毒。隨著抗菌素抗藥性的持續增加，這一趨勢預計將持續下去。對抗這些傳染病的廉價診斷測試、疫苗和治療方法的需求不斷成長預計將推動市場的發展。

由於慢性病的增加和生物防禦措施研發活動的增加，歐洲的生物防禦市場佔據第二大佔有率。

預計2023年至2032年亞太地區生物防禦市場將大幅成長。推動市場成長的主要因素是該地區患者數量的增加。由於流感和 COVID-19 等傳染病的增加，該地區的消費者面臨重大的健康風險。

本報告調查了全球生物防禦市場，提供了市場的定義和概述，市場成長的各種影響因素分析，市場規模推移和預測，各種區分、地區的細分，競爭環境，主要企業概況等彙整資料。

目次

第1章 執行摘要

第2章 市場概要

第3章 研究方法

第4章 市場力学

• 促進要因
  • 加強政府力道與資金投入
  • 疫苗需求不斷增加
• 抑制要因
  • 發展中國家的市場滲透率較低
• 機會
  • 技術進步

第5章 市場要因分析

• 價值鏈分析
• 波特五力分析
• COVID-19 對全球生物防禦市場的影響
• 生物防禦機構預算與補助計畫：依地區劃分

第6章 全球生物防禦市場：依疾病類型

• 概要
• 炭疽菌
• 天花
• 肉毒桿菌
• 流感
• 放射線/核
• 其他

第7章 全球生物防禦市場：依治療方式

• 概要
• 疫苗接種
• 藥品

第8章 全球生物防禦市場：依地區

• 世界
• 北美
• 歐洲
• 亞太地區
• 其他領域

第9章 競合情勢

• 概要
• 競爭基準測試
• 主要成長策略
• 開發專案數量最多的公司
• 主要發展分析
• 主要發展與成長策略
• 主要公司的財務趨勢

第10章 公司簡介

• EMERGENT
• BAVARIAN NORDIC
• ALTIMMUNE
• DYNAVAX TECHNOLOGIES
• SIGA TECHNOLOGIES
• ELUSYS THERAPEUTICS, INC.
• FABENTECH BIOTECH
• CLEVELAND BIOLABS, INC.
• OLOGY BIOSERVICES, INC.
• NOVAVAX, INC.

第11章 附錄

Global Biodefense Market Research Report Information by Disease Type (Anthrax, Smallpox, Botulism, Influenza, Radiation/Nuclear, And Others) by Treatment (Vaccination, And Medication), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

Market Overview

During the forecast period, the Biodefense Market industry is anticipated to grow at a compound annual growth rate (CAGR) of 7.01%.

In preparation for potential bioterrorism attacks, governments are allocating substantial resources to vaccine research and development. Pharmaceutical companies that operate in the biodefense market have been presented with substantial opportunities to expand as a result of government initiatives to prepare for any form of bioterrorism. Additionally, governments worldwide are implementing initiatives to improve their biodefense capabilities. The biodefense market is experiencing growth because of increased funding for research and development, preparedness planning, infrastructure development, and the procurement of vaccines and medications.

Market segment insights

Anthrax, smallpox, botulism, influenza, radiation/nuclear, and other diseases comprise the Biodefense Market segmentation organized by disease type.

The segmentation of the Biodefense Market is based on the treatment, which includes vaccination and medication.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Biodefense market held the greatest market share. This is a result of the increasing prevalence of infectious diseases in the region, including HIV, viral hepatitis, and influenza. For example, the Centers for Disease Control and Prevention (CDC) estimated that approximately 9 million individuals in the United States were diagnosed with the influenza virus in 2021. This trend is anticipated to continue as antimicrobial resistance continues to increase. Furthermore, the market is anticipated to be driven by the increasing demand for affordable diagnostic tests, vaccines, and therapeutics to combat these infectious diseases.

The second-largest market share in the Europe Biodefense market is attributed to the increasing prevalence of chronic diseases and the increase in research and development activities for biodefense solutions throughout the region. Additionally, the German biodefense market was identified as having the greatest market share, while the Rest of Europe biodefense market is anticipated to be the fastest-growing market in the European region.

It is anticipated that the Asia-Pacific Biodefense market will experience substantial growth from 2023 to 2032. The primary factor fueling the market's growth is the rise in the prevalence of the patient population throughout the region. The region's consumers are facing a significant health risk due to the widespread epidemics of infectious diseases, including influenza and Covid-19, as well as the rise in the number of reported infections of communicable diseases. Moreover, the Japan Biodefense market is anticipated to have the highest market share, while the Rest of Asia-Pacific Biodefense market is anticipated to be the fastest-growing market in the Asia-Pacific region.

The Middle East, Africa, and Latin America comprise the Rest of the World. An increase in the prevalence of infectious diseases, including influenza and Covid-19, is expected to drive growth in the biodefense market in the regions.

Major Players

Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US) are among the key companies in the Biodefense Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
  • 1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA MINING
• 3.3 SECONDARY RESEARCH
• 3.4 PRIMARY RESEARCH
  • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING GOVERNMENT INITIATIVES AND FUNDING
  • 4.2.2 RISE IN DEMAND FOR VACCINES
• 4.3 RESTRAINTS
  • 4.3.1 LOW MARKET PENETRATION IN DEVELOPING AND UNDERDEVELOPED COUNTRIES
• 4.4 OPPORTUNITIES
  • 4.4.1 TECHNOLOGICAL ADVANCEMENT

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL BIODEFENSE MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON PRODUCTION
  • 5.3.3 IMPACT ON REGIONS
  • 5.3.4 IMPACT ON PRICING
• 5.4 AUTHORITIES BUDGET AND FINANCING PROGRAMS FOR BIODEFENSE BY REGION

6 GLOBAL BIODEFENSE MARKET, BY DISEASE TYPE

• 6.1 OVERVIEW
• 6.2 ANTHRAX
• 6.3 SMALL POX
• 6.4 BOTULISM
• 6.5 INFLUENZA
• 6.6 RADIATION/NUCLEAR
• 6.7 OTHERS

7 GLOBAL BIODEFENSE MARKET, BY TREATMENT

• 7.1 OVERVIEW
• 7.2 VACCINATION
• 7.3 MEDICATION

8 GLOBAL BIODEFENSE MARKET, BY REGION

• 8.1 GLOBAL OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 UK
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 JAPAN
  • 8.4.2 INDIA
  • 8.4.3 SOUTH KOREA
  • 8.4.4 AUSTRALIA
  • 8.4.5 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 MIDDLE EAST
  • 8.5.2 AFRICA
  • 8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE BENCHMARKING
• 9.3 MAJOR GROWTH STRATEGY IN GLOBAL BIODEFENSE MARKET
• 9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BIODEFENSE MARKET
• 9.5 KEY DEVELOPMENT ANALYSIS
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • 9.6.2 PARTNERSHIP/COLLABORATION/AGREEMENT
  • 9.6.3 ACQUISITION/EXPANSION/INVESTMENT
• 9.7 MAJOR PLAYERS FINANCIAL
  • 9.7.1 SALES,
  • 9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION),

10 COMPANY PROFILE

• 10.1 EMERGENT
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 BAVARIAN NORDIC
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 ALTIMMUNE
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 DYNAVAX TECHNOLOGIES
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 SIGA TECHNOLOGIES
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 KEY STRATEGIES
• 10.6 ELUSYS THERAPEUTICS, INC.
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 KEY STRATEGIES
• 10.7 FABENTECH BIOTECH
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 CLEVELAND BIOLABS, INC.
  • 10.8.1 COMPANY OVERVIEWS
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 OLOGY BIOSERVICES, INC.
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 NOVAVAX, INC.
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 SWOT ANALYSIS
  • 10.10.6 KEY STRATEGIES

11 APPENDIX

• 11.1 REFERENCES
• 11.2 RELATED REPORTS

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
• TABLE 2 BIODEFENSE BUDGET, BY REGION, 2023 (USD MILLION)
• TABLE 3 GLOBAL BIODEFENSE MARKET, 2019-2030 (USD MILLION)
• TABLE 4 GLOBAL BIODEFENSE MARKET, BY REGION, 2019-2030 (USD MILLION)
• TABLE 5 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 6 NORTH AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 7 NORTH AMERICA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 8 NORTH AMERICA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE 2019-2030 (USD MILLION)
• TABLE 9 US: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 10 US: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 11 US: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE,2019-2030 (USD MILLION)
• TABLE 12 CANADA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 13 CANADA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 14 CANADA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 15 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 16 EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 17 EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 18 EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 19 GERMANY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 20 GERMANY: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 21 GERMANY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 22 UK: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 23 UK: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 24 UK: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 25 FRANCE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 26 FRANCE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 27 FRANCE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 28 ITALY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 29 ITALY: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 30 ITALY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 31 SPAIN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 32 SPAIN: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 33 SPAIN: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 34 REST OF EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 35 REST OF EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 36 REST OF EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 37 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 38 ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 39 ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 40 ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 41 JAPAN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 42 JAPAN: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 43 JAPAN: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 44 INDIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 45 INDIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 46 INDIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 47 SOUTH KOREA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 48 SOUTH KOREA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 49 SOUTH KOREA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 50 AUSTRALIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 51 AUSTRALIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 52 AUSTRALIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 53 REST OF ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 54 REST OF ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 55 REST OF ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 56 REST OF THE WORLD: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
• TABLE 57 REST OF THE WORLD: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 58 REST OF THE WORLD: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 59 REST OF THE WORLD: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 60 MIDDLE EAST: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 61 MIDDLE EAST: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 62 MIDDLE EAST: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 63 AFRICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 64 AFRICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 65 AFRICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 66 LATIN AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
• TABLE 67 LATIN AMERICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
• TABLE 68 LATIN AMERICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
• TABLE 69 MAJOR PLAYERS IN GLOBAL BIODEFENSE MARKET
• TABLE 1 MOST ACTIVE PLAYER IN GLOBAL BIODEFENSE MARKET
• TABLE 2 PRODUCT LAUNCH/ PRODUCT APPROVAL
• TABLE 3 PARTNERSHIP/ COLLABORATION /AGREEMENT
• TABLE 4 ACQUISITION/EXPANSION/INVESTMENT
• TABLE 5 EMERGENT: PRODUCTS OFFERED
• TABLE 6 EMERGENT: KEY DEVELOPMENTS
• TABLE 7 BAVARIAN NORDIC: PRODUCTS OFFERED
• TABLE 8 BAVARIAN NORDIC: KEY DEVELOPMENTS
• TABLE 9 ALTIMMUNE: PRODUCTS OFFERED
• TABLE 10 DYNAVAX TECHNOLOGIES: PRODUCTS OFFERED
• TABLE 11 DYNAVAX TECHNOLOGIES: KEY DEVELOPMENTS
• TABLE 12 SIGA TECHNOLOGIES: PRODUCTS OFFERED
• TABLE 13 SIGA TECHNOLOGIES: KEY DEVELOPMENTS
• TABLE 14 ELUSYS THERAPEUTICS, INC.: PRODUCTS OFFERED
• TABLE 15 ELUSYS THERAPEUTICS, INC.: KEY DEVELOPMENTS
• TABLE 16 FABENTECH BIOTECH: PRODUCTS OFFERED
• TABLE 17 FABENTECH BIOTECH: KEY DEVELOPMENTS
• TABLE 18 CLEVELAND BIOLABS, INC.: PRODUCTS OFFERED
• TABLE 19 OLOGY BIOSERVICES, INC.: PRODUCTS OFFERED
• TABLE 20 OLOGY BIOSERVICES, INC.: KEY DEVELOPMENTS
• TABLE 21 NOVAVAX, INC.: PRODUCTS OFFERED
• TABLE 22 NOVAVAX, INC.: KEY DEVELOPMENTS

LIST OF FIGURES

• FIGURE 1 GLOBAL BIODEFENSE MARKET STRUCTURE
• FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
• FIGURE 3 MARKET DYNAMICS: GLOBAL BIODEFENSE MARKET
• FIGURE 4 DRIVER IMPACT ANALYSIS
• FIGURE 5 RESTRAINT IMPACT ANALYSIS
• FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL BIODEFENSE MARKET
• FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL BIODEFENSE MARKET
• FIGURE 8 GLOBAL BIODEFENSE MARKET; DISEASE TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)
• FIGURE 9 GLOBAL BIODEFENSE MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION)
• FIGURE 10 GLOBAL BIODEFENSE MARKET SHARE, BY REGION, 2023 (% SHARE)
• FIGURE 11 GLOBAL BIODEFENSE MARKET, BY REGION, 2023 & 2030 (USD MILLION)
• FIGURE 12 NORTH AMERICA MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
• FIGURE 13 NORTH AMERICA: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
• FIGURE 14 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
• FIGURE 15 EUROPE MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
• FIGURE 16 EUROPE: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
• FIGURE 17 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
• FIGURE 18 ASIA-PACIFIC MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
• FIGURE 19 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019 & 2030 (USD MILLION)
• FIGURE 20 ASIA-PACIFIC: BIODEFENSE MARKET SHARE (%), BY COUNTRY,
• FIGURE 21 REST OF THE WORLD MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
• FIGURE 22 REST OT THE WORLD: BIODEFENSE MARKET, BY REGION, 2019 & 2030 (USD MILLION)
• FIGURE 23 REST OF THE WORLD: BIODEFENSE MARKET SHARE (%), BY COUNTRY,
• FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS
• FIGURE 25 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL BIODEFENSE MARKET
• FIGURE 26 GLOBAL BIODEFENSE MARKET: COMPETITIVE LANDSCAPE
• FIGURE 27 MAJOR PLAYERS SALES,
• FIGURE 28 MAJOR PLAYERS R&D EXPENDITURE,
• FIGURE 29 EMERGENT: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 30 EMERGENT: SWOT ANALYSIS
• FIGURE 31 BAVARIAN NORDIC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 32 BAVARIAN NORDIC: SWOT ANALYSIS
• FIGURE 33 ALTIMMUNE: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 34 DYNAVAX TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 SIGA TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 36 SIGA TECHNOLOGIES: SWOT ANALYSIS
• FIGURE 37 FABENTECH BIOTECH: SWOT ANALYSIS
• FIGURE 38 CLEVELAND BIOLABS, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 39 NOVAVAX, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 40 NOVAVAX, INC.: SWOT ANALYSIS